CareDx, Inc. announced on April 15 2026 that it will divest its Lab Products business to EuroBio Scientific for $170 million in cash. The transaction is expected to close by the end of CareDx’s third quarter of 2026 and is subject to customary conditions and regulatory approvals, including a Swedish regulatory review.
The divestiture is intended to sharpen CareDx’s focus on its high‑growth Testing Services and Patient & Digital Solutions segments. "This divestiture allows us to strategically focus on our core Testing Services and Patient and Digital Solutions, where our solutions‑selling strategy is working," said John Hanna, President and CEO of CareDx.
EuroBio Scientific, a leading French in‑vitro diagnostics group, will acquire CareDx’s portfolio of IVD PCR kits for HLA typing and transplant monitoring assays. "This acquisition marks a significant milestone in our mission to advance precision medicine in transplantation. By combining our technological leadership with CareDx's strong Lab Products portfolio, we are uniquely positioned to deliver comprehensive solutions to transplant laboratories worldwide," said Denis Fortier, CEO of EuroBio Scientific.
CareDx’s preliminary Q1 2026 results show total revenue of $118 million, up 39% year‑over‑year. Testing Services revenue rose to $91 million, a 48% increase, driven by robust demand for precision‑medicine testing. Patient & Digital Solutions revenue grew to $16 million, up 33%, reflecting expansion of digital platforms. In contrast, Lab Products revenue fell to $10 million, a 4% decline, underscoring the segment’s weaker performance and the rationale for its sale.
Investors reacted positively to the announcement and the strong Q1 results, reflecting confidence in CareDx’s strategic focus on its core high‑growth businesses.
The $170 million cash infusion will strengthen CareDx’s balance sheet and support margin expansion. The company will retain exclusive perpetual rights to distribute post‑transplant monitoring IVD tests in North America, including AlloSeq cfDNA, ensuring continued revenue streams from its core diagnostics portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.